Trial Profile
An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin With/Without OADs in Type 2 Diabetes (BEGIN™: BB)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine; Metformin; Pioglitazone
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms BEGIN:BB
- Sponsors Novo Nordisk